The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Accelerate Diagnostics Inc | COM | 00430H102 | 1,684 | 117,176 | SH | SOLE | 1 | 117,176 | 0 | 0 | |
| Achillion Pharmaceuticals Inc | COM | 00448Q201 | 19,754 | 2,558,859 | SH | SOLE | 1 | 2,558,859 | 0 | 0 | |
| Agenus Inc | COM NEW | 00847G705 | 10,044 | 2,414,524 | SH | SOLE | 1 | 2,414,524 | 0 | 0 | |
| Atara Biotherapeutics Inc. | COM | 046513107 | 9,004 | 473,126 | SH | SOLE | 1 | 473,126 | 0 | 0 | |
| Berkshire Hathaway Inc | CL B NEW | 084670702 | 7 | 50 | SH | SOLE | 1 | 50 | 0 | 0 | |
| bluebird bio Inc | COM | 09609G100 | 9,621 | 226,371 | SH | SOLE | 1 | 226,371 | 0 | 0 | |
| Celldex Therapeutics Inc | COM | 15117B103 | 3,740 | 989,376 | SH | SOLE | 1 | 989,376 | 0 | 0 | |
| CytRx Corp | COM PAR $.001 | 232828509 | 1,375 | 513,092 | SH | SOLE | 1 | 513,092 | 0 | 0 | |
| Dicerna Pharmaceuticals Inc | COM | 253031108 | 10,864 | 2,026,894 | SH | SOLE | 1 | 2,026,894 | 0 | 0 | |
| Five Prime Therapeutics Inc | COM | 33830X104 | 9,223 | 226,998 | SH | SOLE | 1 | 226,998 | 0 | 0 | |
| Incyte Corp | COM | 45337C102 | 27,496 | 379,415 | SH | SOLE | 1 | 379,415 | 0 | 0 | |
| iShares 20+ Year Treasury Bond ETF | 20 YR TR BD ETF | 464287432 | 3,918 | 30,000 | SH | SOLE | 1 | 30,000 | 0 | 0 | |
| Kite Pharma Inc | COM | 49803L109 | 15,770 | 343,503 | SH | SOLE | 1 | 343,503 | 0 | 0 | |
| Mirati Therapeutics Inc | COM | 60468T105 | 9,169 | 428,457 | SH | SOLE | 1 | 428,457 | 0 | 0 | |
| MNKD 01/20/2017 PUT 3 | COM | 56400P201 | 899 | 4,385 | SH | Put | SOLE | 1 | 4,385 | 0 | 0 |
| NVRO 05/20/2016 PUT 50 | COM | 64157F103 | 36 | 142 | SH | Put | SOLE | 1 | 142 | 0 | 0 |
| Omeros Corp | COM | 682143102 | 13,676 | 891,522 | SH | SOLE | 1 | 891,522 | 0 | 0 | |
| Allscripts Healthcare Solutions Inc | COM | 01988P108 | 634 | 48,000 | SH | SOLE | 1 | 48,000 | 0 | 0 | |
| Natera Inc | COM | 632307104 | 302 | 31,693 | SH | SOLE | 1 | 31,693 | 0 | 0 | |
| Adaptimmune Therapeutics-adr | SPONDS ADR | 00653A107 | 63 | 7,691 | SH | SOLE | 1 | 7,691 | 0 | 0 | |
| Alnylam Pharmaceuticals Inc | COM | 02043Q107 | 54,383 | 866,379 | SH | SOLE | 1 | 866,379 | 0 | 0 | |
| Avexis Inc | COM | 05366U100 | 12,895 | 473,374 | SH | SOLE | 1 | 473,374 | 0 | 0 | |
| BioCryst Pharmaceuticals Inc | COM | 09058V103 | 5,586 | 1,973,932 | SH | SOLE | 1 | 1,973,932 | 0 | 0 | |
| Biopharmx Corp | COM | 09072X101 | 764 | 700,636 | SH | SOLE | 1 | 700,636 | 0 | 0 | |
| Bristol-Myers Squibb Co | COM | 110122108 | 7,008 | 109,701 | SH | SOLE | 1 | 109,701 | 0 | 0 | |
| Corium International Inc | COM | 21887L107 | 3,197 | 828,332 | SH | SOLE | 1 | 828,332 | 0 | 0 | |
| Global Blood Therapeutics Inc | COM | 37890U108 | 3,029 | 190,981 | SH | SOLE | 1 | 190,981 | 0 | 0 | |
| Invuity Inc | COM NEW | 46187J205 | 1,536 | 212,808 | SH | SOLE | 1 | 212,808 | 0 | 0 | |
| La Jolla Pharmaceutical Co | COM PAR $.0001 2 | 503459604 | 24,445 | 1,169,065 | SH | SOLE | 1 | 1,169,065 | 0 | 0 | |
| Lipocine Inc | COM | 53630X104 | 2,440 | 240,438 | SH | SOLE | 1 | 240,438 | 0 | 0 | |
| Regenxbio Inc | COM | 75901B107 | 2,606 | 241,323 | SH | SOLE | 1 | 241,323 | 0 | 0 | |
| Symmetry Surgical Inc | COM | 87159G100 | 9,068 | 919,680 | SH | SOLE | 1 | 919,680 | 0 | 0 | |
| Nivalis Therapeutics Inc | COM | 65481J109 | 125 | 30,000 | SH | SOLE | 1 | 30,000 | 0 | 0 | |
| Masimo Corp | COM | 574795100 | 1,084 | 25,900 | SH | SOLE | 1 | 25,900 | 0 | 0 | |